Literature DB >> 10094431

Characterization of phenytoin-resistant kindled rats, a new model of drug-resistant partial epilepsy: influence of experimental and environmental factors.

U Ebert1, C Rundfeldt, H Lehmann, W Löscher.   

Abstract

It has been recently shown that the variable anticonvulsant effect of phenytoin in the kindling model is not a characteristic of all kindled rats. In a population of amygdala-kindled Wistar rats, subgroups can be selected which consistently respond to phenytoin with an increase in afterdischarge threshold (responders) or which never show such an increase (non-responders). This study examined retrospectively the influence of technical and environmental factors on the results of several prospectively performed phenytoin selections during the last few years. Male and female Wistar rats were implanted with bipolar electrodes aimed at the basolateral amygdala and subsequently kindled. The fully kindled rats were tested for their ability to consistently respond to phenytoin (75 mg/kg i.p.) with an increase of afterdischarge threshold in three consecutive trials. Analysis of 158 Wistar rats of both genders revealed no significant influence of either plasma concentration of phenytoin, kindling parameters, precise electrode location, or differences in focal histology on the result of phenytoin selection. Furthermore, the ability to respond to phenytoin was not associated with the season or the ambient atmospheric pressure during the selection procedure. The data suggest that the difference between phenytoin responders and non-responders is not due to experimental factors, but may rather be genetically determined.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10094431     DOI: 10.1016/s0920-1211(98)00086-2

Source DB:  PubMed          Journal:  Epilepsy Res        ISSN: 0920-1211            Impact factor:   3.045


  4 in total

Review 1.  Validated animal models for antiseizure drug (ASD) discovery: Advantages and potential pitfalls in ASD screening.

Authors:  Melissa Barker-Haliski; H Steve White
Journal:  Neuropharmacology       Date:  2019-08-27       Impact factor: 5.250

Review 2.  Issues related to development of new antiseizure treatments.

Authors:  Karen S Wilcox; Tracy Dixon-Salazar; Graeme J Sills; Elinor Ben-Menachem; H Steve White; Roger J Porter; Marc A Dichter; Solomon L Moshé; Jeffrey L Noebels; Michael D Privitera; Michael A Rogawski
Journal:  Epilepsia       Date:  2013-08       Impact factor: 5.864

3.  Antiseizure drug efficacy and tolerability in established and novel drug discovery seizure models in outbred vs inbred mice.

Authors:  Zachery Koneval; Kevin M Knox; Ali Memon; Dannielle K Zierath; H Steve White; Melissa Barker-Haliski
Journal:  Epilepsia       Date:  2020-08-05       Impact factor: 5.864

Review 4.  Climate change and epilepsy: Insights from clinical and basic science studies.

Authors:  Medine I Gulcebi; Emanuele Bartolini; Omay Lee; Christos Panagiotis Lisgaras; Filiz Onat; Janet Mifsud; Pasquale Striano; Annamaria Vezzani; Michael S Hildebrand; Diego Jimenez-Jimenez; Larry Junck; David Lewis-Smith; Ingrid E Scheffer; Roland D Thijs; Sameer M Zuberi; Stephen Blenkinsop; Hayley J Fowler; Aideen Foley; Sanjay M Sisodiya
Journal:  Epilepsy Behav       Date:  2021-02-10       Impact factor: 3.337

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.